https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53997 Wed 28 Feb 2024 16:40:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51939 Wed 28 Feb 2024 15:27:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53837 Wed 28 Feb 2024 15:17:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54893 Wed 20 Mar 2024 13:33:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51050 Wed 16 Aug 2023 12:22:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50616 Wed 15 May 2024 14:22:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43989 Wed 13 Mar 2024 19:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40474 Wed 13 Mar 2024 08:52:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44371 Wed 12 Oct 2022 11:07:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28317 Wed 11 Apr 2018 12:08:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27693 Wed 11 Apr 2018 10:30:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28163 Wed 11 Apr 2018 10:07:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23398 Wed 11 Apr 2018 10:02:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43939 Wed 05 Oct 2022 12:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43929 Wed 05 Oct 2022 12:37:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52166 Wed 04 Oct 2023 10:56:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55012 Wed 03 Apr 2024 10:47:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53292 Tue 21 Nov 2023 11:47:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52364 Tue 10 Oct 2023 14:16:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45990 Tue 08 Nov 2022 15:01:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51192 150 mm Hg) after thrombolysis treatment for acute ischaemic stroke between March 3, 2012 and April 30, 2018. Methods: All available brain imaging were analysed centrally by expert readers. Log-linear regression was used to determine the effects of intensive blood pressure lowering on the size of cerebral infarction, with adjustment for potential confounders. The primary analysis pertained to follow-up computerised tomography (CT) scans done between 24 and 36 h. Sensitivity analysis were undertaken in patients with only a follow-up magnetic resonance imaging (MRI) and either MRI or CT at 24–36 h, and in patients with any brain imaging done at any time during follow-up. This trial is registered with ClinicalTrials.gov, number NCT01422616. Findings: There were 1477 (67.3%) patients (mean age 67.7 [12.1] y; male 60%, Asian 65%) with available follow-up brain imaging for analysis, including 635 patients with a CT done at 24–36 h. Mean achieved systolic blood pressures over 1–24 h were 141 mm Hg and 149 mm Hg in the intensive group and guideline group, respectively. There was no effect of intensive blood pressure lowering on the median size (ml) of cerebral infarction on follow-up CT at 24–36 h (0.3 [IQR 0.0–16.6] in the intensive group and 0.9 [0.0–12.5] in the guideline group; log Δmean −0.17, 95% CI −0.78 to 0.43). The results were consistent in sensitivity and subgroup analyses. Interpretation: Intensive blood pressure lowering treatment to a systolic target <140 mm Hg within several hours after the onset of symptoms may not increase the size of cerebral infarction in patients who receive thrombolysis treatment for acute ischaemic stroke of mild to moderate neurological severity. Funding: National Health and Medical Research Council of Australia; UK Stroke Association; UK Dementia Research Institute; Ministry of Health and the National Council for Scientific and Technological Development of Brazil; Ministry for Health, Welfare, and Family Affairs of South Korea; Takeda.]]> Thu 24 Aug 2023 14:38:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8228 Sat 24 Mar 2018 08:40:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13923 Sat 24 Mar 2018 08:24:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11323 Sat 24 Mar 2018 08:12:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19000 Sat 24 Mar 2018 08:05:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21475 Sat 24 Mar 2018 08:03:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20559 Sat 24 Mar 2018 08:02:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20294 Sat 24 Mar 2018 07:55:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21549 Sat 24 Mar 2018 07:50:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27777 Sat 24 Mar 2018 07:37:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26364 Sat 24 Mar 2018 07:33:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27055 Sat 24 Mar 2018 07:25:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23364 0.5 ng/mL) alone and when assessed in conjunction with the randomised treatment group increased risk of PCSM in the US trial (PSA nadir p=0.0016; PSA end p=0.017) and Australasian trial (PSA nadir p<0.0001; PSA end p=0.0012). In both trials, the randomised treatment group was no longer associated with PCSM (p>=0.20) when the candidate surrogates were included in the model. Therefore, both PSA metrics satisfied Prentice criteria for surrogacy. INTERPRETATION: After radiotherapy and 6 months of androgen suppression, men with PSA end values exceeding 0.5 ng/mL should be considered for long-term androgen suppression and those with localised or locally advanced prostate cancer with PSA nadir values exceeding 0.5 ng/mL should be considered for inclusion in randomised trials investigating the use of drugs that have extended survival in castration-resistant metastatic prostate cancer.]]> Sat 24 Mar 2018 07:16:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23407 Sat 24 Mar 2018 07:13:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24985 Sat 24 Mar 2018 07:09:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24188 Sat 24 Mar 2018 07:09:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52865 Mon 30 Oct 2023 10:01:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50774 Mon 29 Jan 2024 18:43:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53157 Mon 27 Nov 2023 15:05:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52532 Mon 16 Oct 2023 16:35:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51594 Mon 11 Sep 2023 15:59:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54742 Mon 11 Mar 2024 14:26:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23890 Fri 28 Oct 2016 16:21:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50581 Fri 28 Jul 2023 14:36:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46571 Fri 25 Nov 2022 11:47:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53044 Fri 17 Nov 2023 11:47:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53115 Fri 17 Nov 2023 11:27:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39704 Fri 17 Jun 2022 16:56:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49414 Fri 12 May 2023 15:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41264 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vsvsvs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin cancer. No excess of fractures or cardiovascular disease was observed. Interpretation: This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.]]> Fri 11 Aug 2023 16:56:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28315 Fri 06 Oct 2023 16:24:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55264 Fri 03 May 2024 15:29:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55252 Fri 03 May 2024 15:24:23 AEST ]]>